On December 6, 2025, Fulcrum Therapeutics released initial results from the 20 mg dose in their Phase 1b PIONEER trial for sickle cell disease, showing a 9.9% increase in fetal hemoglobin levels and improved patient outcomes, with 58% of patients achieving levels ≥20%. This event is significant for the company's ongoing clinical development and could impact future treatments.